SCHEMBL14427201

SCHEMBL14427201

COc1cc2c(cc1OC)C(C(=O)O)N(S(=O)(=O)c1ccc(-c3ccc(Cl)cc3)cc1)CC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ MMP1 P03956 5/20 0.55
▸ MMP2 P08253 5/20 0.55
▸ MMP9 P14780 5/20 0.55
▸ MMP12 P39900 5/20 0.55
▸ MMP14 P50281 5/20 0.55
▸ MMP15 P51511 5/20 0.55
▸ MMP16 P51512 5/20 0.55
▸ MMP26 Q9NRE1 5/20 0.55
▸ MMP7 P09237 4/20 0.55
▸ CA1 P00915 4/20 0.53
▸ CA2 P00918 4/20 0.53
▸ CA9 Q16790 4/20 0.53
▸ CA14 Q9ULX7 4/20 0.53
▸ CA7 P43166 3/20 0.50
▸ DRD2 P14416 1/20 0.50
▸ HTR2A P28223 1/20 0.50
▸ HTR2C P28335 1/20 0.50
▸ DRD3 P35462 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14427197 0.89 MMP12 (0.69) MEN1KMT2AMMP1MMP2MMP9
SCHEMBL5430819 0.83 CA1 (0.53) MEN1KMT2AMMP1MMP2MMP9
SCHEMBL14427204 0.81 MMP8 (0.54) MEN1KMT2AMMP1MMP2MMP9
SCHEMBL14427211 0.78 PSEN1 (0.42) MEN1KMT2AMMP1MMP2MMP9
SCHEMBL12215822 0.74 MMP8 (0.42) MEN1KMT2AMMP1MMP2MMP9
SCHEMBL14427181 0.74 MMP8 (0.56) MMP1MMP2MMP9MMP12MMP14
SCHEMBL14427213 0.70 PSEN1 (0.42) MEN1KMT2AMMP1MMP2MMP9
SCHEMBL23752390 0.70 MMP1 (1.00) MMP1MMP2MMP9MMP12MMP14
SCHEMBL14427210 0.70 MMP1 (0.48) MMP1MMP2MMP9MMP12MMP14
SCHEMBL14427297 0.70 MMP1 (0.48) MMP1MMP2MMP9MMP12MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-30 — — US disclosed
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS MMP9, MMP2, MMP3 MEN1 1780/4885KMT2A 687/4885MMP1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback